Disclosed herein is a glycoconjugate vaccine conferring protection against a Gram negative pathogen infection, a method of manufacturing the glycoconjugate vaccine, and use of the glycoconjugate vaccine for treating bacterial infection. The glycoconjugate vaccine of the present disclosure has the structure of formula (I), wherein, L is a maleimide-type linker, which is connected to the carrier protein via a maleimide bond formed therebetween; and n and m are independently an integral or a non-integral number between 2 and 20.